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364Objective: This meta-analysis of randomized, controlled trials evaluated effects of statins on postoperative atrial
fibrillation risk after cardiac surgery.
Methods: Randomized, controlled trials evaluating statins in cardiac surgery were selected from MEDLINE
(1996–August 2009), Cochrane CENTRAL Register, and manual review of references without any language re-
strictions. End points examined included postoperative atrial fibrillation, intensive care unit stay, and total hos-
pital stay. Meta-regression analyses were conducted to determine whether statins’ effects were duration or dose
dependent. A random-effects model was used in all instances.
Results: Eight trials (n¼ 774) were identified and subjected to meta-analysis. Statins reduced postoperative atrial
fibrillation risk (relative risk 0.57, 95% confidence interval 0.45–0.72, P< .0001, risk difference0.14, 95%
confidence interval 0.20 to 0.08, P< .0001, number needed to treat 8) and total hospital stay (weighted
mean difference0.66 days, 95% confidence interval1.01 to0.30 days, P ¼ .0004) relative to placebo. Inten-
sive care unit stay was also reduced (weighted mean difference0.17 days, 95% confidence interval0.37 to 0.03
days, P ¼ .09) but did not meet prespecified criteria for statistical significance. Metaregression analysis revealed
association between duration of preoperative statin prophylaxis and postoperative atrial fibrillation risk reduction
(3% reduction per day, P ¼ .008). No association was found between statin dose used and risk reduction
(P ¼ .47).
Conclusions: Evidence suggests that statins are associated with reduced risk of postoperative atrial fibrillation
and shorter hospital stay after cardiac surgery and that earlier therapy results in more profound benefit. (J Thorac
Cardiovasc Surg 2010;140:364-72)One of the most common complications after cardiac sur-
gery (coronary artery bypass grafting or valve surgery) is
the development of postoperative atrial fibrillation (AF).1-3
Although typically self-limiting, postoperative AF can in-
crease a patient’s risk for hemodynamic instability and
stroke. Moreover, it prolongs hospital stay and increases to-
tal hospital costs.3,4 b-Blockers and amiodarone are
commonly used to prevent postoperative AF; even when
these agents are used, however, the development of
postoperative AF is still common.4-6
Inflammation may be a causal factor in the development
of postoperative AF.1,7-9 Because of the ability of
hydroxymethylglutaryl coenzyme A reductase inhibitors
(statins) to attenuate inflammation,10-11 researchers have
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The Journal of Thoracic and Cardiovascular Surgbefore cardiac surgery and the subsequent development of
postoperative AF. Previous meta-analyses have evaluated
this topic, but their findings were driven by observational
studies and consequently subject to bias.12,13 More
recently, well-designed randomized, controlled trials have
appeared in the literature; however, these trials have in-
cluded relatively small numbers of patients and statin regi-
mens varying in both duration and dosing intensity and
therefore have shown mixed results. To understand better
the effects of statins on postoperative AF and subsequent
hospital stay after cardiac surgery, we performed meta-
analysis and duration- and dose-response metaregression
analyses of relevant randomized, controlled trials.MATERIALS AND METHODS
A protocol was prospectively developed outlining the criteria for trial se-
lection, outcomes of interest, the approach to assessing trial quality, and the
statistical methodology. Preparation of this report was in accordance with
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement for the reporting of systematic reviews and meta-anal-
yses.14
Study Selection
A systematic literature search of MEDLINE (1996–August 2009) and
the Cochrane CENTRALRegister (2009, issue 2) was conducted to identify
all relevant trials. The MEDLINE search strategy used in OVID, shown in
Appendix 1, used the Cochrane Collaboration’s Highly Sensitive Searchery c August 2010
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CI ¼ confidence interval
RR ¼ relative risk
ICU ¼ intensive care unit
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human subjects. No language restrictions were imposed. A search of Google
Scholar and a manual search of references from reports of clinical trials or
review articles to identify additional relevant studies were also conducted.
Included trials had (1) to be randomized trials of a statin, (2) to be pla-
cebo controlled or open label, and (3) to report data on either the proportion
of patients with postoperative AF or total hospital and intensive care unit
(ICU) stays. With these prespecified inclusion criteria, 3 investigators
(W.T.C., G.M.K., and C.I.C.) reviewed all potentially relevant articles inde-
pendently, with disagreement among investigators resolved by consensus.
When applicable, efforts were made to contact investigators for clarification
or additional required data.
Validity Assessment
The following methodologic features most relevant to the control of bias
were assessed: randomization, random allocation concealment, masking of
treatment allocation, blinding, and reporting of withdrawals. Jadad scores
were calculated to aid in the identification of reports with overall weaker
study methodologies.16 All studies were reviewed and evaluated by 2 re-
viewers (W.T.C. and G.M.K.), with disagreement between investigators re-
solved by consensus.
Data Abstraction
Two investigators (W.T.C. and G.M.K.) independently abstracted all
data with a standardized data-abstraction tool, and disagreements were re-
solved by a third party (C.I.C.). The following information was sought
from each article: author identification, year of publication, study design
(method of random allocation, extent of blinding), study population and
perioperative characteristics, sample size, duration of patient follow-up, sta-
tin regimen used (drug, dose, and duration), type of surgery performed (cor-
onary artery bypass grafting, valve, or combination surgery), use of
cardiopulmonary bypass, and definitions of and data for aforementioned
study end points. Attempts were made to contact authors of included studies
to clarify or collect additional data.
Statistical Analysis
The incidence of postoperative AF was treated as a dichotomous vari-
able, and total hospital and ICU stays were treated as continuous variables.
Information from individual trials was combined with a DerSimonian and
Laird random-effects model. The pooled estimates of effect were reported
as either relative risks (RRs) with risk differences (absolute risk reductions)
and numbers needed to treat (for postoperative AF) or weighted mean dif-
ferences (for stay end points) with accompanying 95% confidence intervals
(CIs). Calculations of RRs are problematic for individual studies with an ab-
sence of events in the treatment or placebo group. For these studies, a nom-
inal value (0.5) was added in all 23 2 cells to enable calculation of RRs.15
Statistical heterogeneity was addressed with the I2 statistic, which as-
sesses the degree of inconsistency across studies and ranges from 0% to
100%, with higher percentages representing higher likelihood of heteroge-
neity. Whereas categorization of values for I2 may not be appropriate in all
situations, I2 values of 25%, 50%, and 75% have been regarded as repre-
sentative of low, medium, and high statistical heterogeneities, respectively.
We used visual inspection of funnel plots, Egger’s weighted regressionThe Journal of Thoracic and Castatistics, and the trim and fill method to assess for and quantify the effects
of publication bias. The trim and fill method uses funnel plot symmetry to
estimate the number of ‘‘missing’’ studies and the magnitudes of their ef-
fects. It estimates the overall effect size again after imputation of potentially
missing studies into the meta-analysis to determine whether the results of
the original analysis are replicated. Statistics were performed with StatsDir-
ect statistical software, version 2.7.2 (StatsDirect Ltd, Altrincham, United
Kingdom), and MIX statistical software (Bax L, Yu LM, Ikeda N, Tsuruta
N, Moons KG. MIX: comprehensive free software for meta-analysis of
causal research data—version 1.7. 2008. Available at http://www.mix-for-
meta-analysis.info).
To establish the effect of heterogeneity between studies on the conclu-
sions of this meta-analysis, subgroup and sensitivity analyses were con-
ducted. The effect of variations in surgery type (involvement of valve
surgery), surgical technique (excluding studies with any use of off-pump
cardiopulmonary bypass surgery), and methodological quality (excluding
studies with Jadad scores<3) were assessed. In addition, an analysis exclud-
ing trials with control rates of postoperative AF at the extreme ends or out-
side the norm was conducted.2 Finally, the effect of alternatively using
a fixed-effect (Mantel–Haenszel) model for pooling data was evaluated.
We further evaluated the effects of preoperative statin duration and dos-
ing intensity (all statin doses converted to atorvastatin equivalents with the
following ratios: atorvastatin 10 mg equivalent to simvastatin 5–20 mg, pra-
vastatin 10–40 mg, or fluvastatin 20–80 mg; atorvastatin 20 mg equivalent
to simvastatin 40 mg, pravastatin 80 mg, or rosuvastatin 5 mg; atorvastatin
40 mg equivalent to simvastatin 80 mg or rosuvastatin 10 mg; and atorvas-
tatin 80 mg equivalent to rosuvastatin 20 mg) on postoperative AF risk with
random-effects metaregression estimation through iterative maximum like-
lihood.Metaregression analysis is an indirect way to examine the possibility
of effect modification by duration of treatment. The logarithmically trans-
formed RR of postoperative AF was examined. Metaregression analysis
was performed with SPSS software, version 17.0 (SPSS Inc, Chicago, Ill).RESULTS
The flow of trial inclusion and exclusion is depicted in
Figure 1. Ultimately, 8 randomized controlled trials pub-
lished between 1999 and 2009 from 6 different countries
met our eligibility criteria.17-24 Key characteristics of
included trials can be found in Table 1. Individual trial sizes
ranged from 40 to 200 patients, and the total sample size was
774 (389 patients in the statin group and 385 patients in the
control group). Specific statins used in trials included the fol-
lowing: atorvastatin (20 and 40mg), fluvastatin (80mg), pra-
vastatin (40 mg), rosuvastatin (20 mg), and simvastatin (20
mg). This corresponds to an atorvastatin dosing equivalent
range of 10 to 80 mg. Preoperative duration of statin use
ranged from as little as 2 days to as long as 4 weeks (2
days–3 weeks for trials reporting the postoperative AF end
point). Only 1 trial allowed patients undergoing valve sur-
gery (with or without coronary artery bypass grafting) to be
randomly allocated.17 Similarly, only 1 trial allowed patients
undergoing off-pump surgery to be enrolled.18 Data on the
routine use of postoperative b-blockers and amiodarone to
prevent postoperative AF were not consistently reported
within trials. Six of the 8 included trials evaluated the postop-
erative AF end point,17-22 whereas 5 and 6 trials evaluated
total ICU stay18,21-24 and total hospital stay,17-19,22-24
respectively. Definitions and duration of monitoring for
postoperative AF were not detailed in 3 trials.20-22 Of therdiovascular Surgery c Volume 140, Number 2 365
FIGURE 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart. RCT, Randomized, controlled trial; CTS, cardio-
thoracic surgery.
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documented AF longer than 5 minutes in duration or AF
episodes requiring intervention for symptoms or
hemodynamic compromise and assessed patients with
telemetric monitoring for a minimum of 6 postoperative
days.17,18 The last trial used electrocardiograms taken on
admission to the ICU, 12 hours later, and every day
thereafter until hospital discharge.19
Quantitative Data Synthesis
Postoperative AF. Onmeta-analysis of the 6 trials (n¼ 651)
evaluating postoperative AF,17-22 statin use was found to
reduce patients’ RR of development of postoperative AF by
43% (RR 0.57, 95% CI 0.45–0.72; Figure 2) and their abso-
lute risk by 14% (95% CI 8%–20%). This corresponds to
a number needed to treat of 8 (95% CI 5–13). No statistical
heterogeneity was observed for these analyses (I2 ¼ 0 for
both). The Egger’s statisticP value suggested a low likelihood
of publication bias (P> .17 for both). Trim and fill analysis
suggests that any publication bias that might exist was not
likely to effect our meta-analyses’ overall conclusions regard-
ing postoperative AF (Table 2).
Metaregression analysis suggested a statistically signifi-
cant correlation (Ln RR ¼ [0.0283 3 Duration]0.4781,366 The Journal of Thoracic and Cardiovascular SurgP ¼ .008) between preoperative duration of statin use and
a patient’s RR reduction of postoperative AF (Figure 3
and Table 3). No statistically significant correlation was
seen when evaluating statin dose (P ¼ .47). The meta-anal-
yses’ conclusions regarding postoperative AF were not al-
tered by conduction of various sensitivity analyses.
Length of stay. Pooled analysis of 5 trials18,21-24 (n¼ 331)
suggested a 0.17 day decrease in ICU stay with preoperative
statin use; however, this end point failed to reach statistical
significance (P¼ .10). On meta-analysis of 6 trials (n¼ 687)
evaluating total hospital stay,17-19,22-24 statin use was found
to reduce patients’ stay statistically significantly by two-
thirds of a day. Small to moderate degrees of statistical het-
erogeneity were observed in both these analyses (I2 ¼ 24%
and 47%, respectively). As with the postoperative AF end
point, publication bias was deemed to be unlikely (Egger’s
P value>0.19 for both) or alter our meta-analyses’ overall
conclusions for these end points. The meta-analytic conclu-
sions regarding ICU and total stays were not altered by con-
duction of various sensitivity analyses.
DISCUSSION
In this meta-analysis of 8 randomized, controlled trials,
patients receiving statins had a lower risk of developmentery c August 2010
TABLE 1. Characteristics of included randomized controlled trials of statins in cardiac surgery
Berkan,
200923
Caorsi,
200820
Mannacio,
200819
Song,
200818
Tamayo,
200821
Chello,
200622
Patti,
200617
Christenson,
199924
Demographic data
No. of patients
Statin 23 21 100 62 22 20 101 40
Control 23 22 100 62 22 20 99 37
Age (y, mean)
Statin 65 68 61 62 68 66 66 63
Control 68 68 59 64 68 64 67 64
Sex (% male)
Statin 61 81 75 63 77 80 79 78
Control 65 86 70 68 82 75 68 84
Medical history
Diabetes mellitus (%)
Statin 35 38 0 47 27 0 32 23
Control 39 41 0 52 41 0 42 24
Previous myocardial infarction (%)
Statin NR 0 21 13 0 0 47 55
Control NR 0 25 8 0 0 38 59
Previous atrial fibrillation (%)
Statin NR NR NR 0 NR NR 0 NR
Control NR NR NR 0 NR NR 0 NR
Previous medications
Angiotensin-converting enzyme inhibitors (%)
Statin NR 0 22 57 32* NR 47 NR
Control NR 0 28 50 55* NR 52 NR
Amiodarone (%)
Statin NR NR 10 NR NR NR 1 NR
Control NR NR 12 NR NR NR 1 NR
b-Blockers (%)
Statin NR NR 73 73 27 30 72 NR
Control NR NR 68 69 46 35 60 NR
Surgery type
On pump (%)
Statin 100 100 100 0 100 100 100 100
Control 100 100 100 0 100 100 100 100
Coronary artery bypass grafting (%)
Statin 100 100 100 100 100 100 83 100
Control 100 100 100 100 100 100 75 100
Valve surgery (%)
Statin 0 0 0 0 0 0 16y 0
Control 0 0 0 0 0 0 25y 0
Perioperative data
CPB time (min)
Statin 122 94 81 NA 107 97 113 78
Control 113 94 84 NA 96 94 105 82
Crossclamp time (min)
Statin 73 63 42 NA 70 49 76 64
Control 71 63 40 NA 63 52 73 61
Inotrope use (%)
Statin 9 NR 11 63 60 25 30 NR
Control 30 NR 25 68 41 30 25 NR
Intra-aortic balloon pump support (%)
Statin 4 NR 0 5 NR NR NR NR
Control 13 NR 1 3 NR NR NR NR
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TABLE 1. Continued
Berkan,
200923
Caorsi,
200820
Mannacio,
200819
Song,
200818
Tamayo,
200821
Chello,
200622
Patti,
200617
Christenson,
199924
Intervention Fluvastatin
80 mg/d vs
placebo for
21 d preop
Pravastatin
40 mg/d for
48 h preop,
extra 40 mg
dose 1 h post
CPB, contd
7 d postop vs
no treatment
Rosuvastatin
20 mg/d vs
placebo for
7 d preop
Atorvastatin
20 mg/d for
3 d preop,
contd for 30
d postop vs
no treatment
Simvastatin
20 mg/d for
21 wk preop
vs no
treatment
Atorvastatin
20 mg/d vs
placebo for
21 d preop
Atorvastatin 40
mg/d vs
placebo for
7 d preop,
contd to
discharge
Simvastatin
20 mg/d for
28 d preop
vs no
treatment
Jadad scorez 3 (1, 2, 1) 1 (1, 0, 0) 3 (1, 2, 0) 3 (2, 0, 1) 2 (1, 1, 0) 3 (1, 2, 0) 4 (2, 2, 0) 1 (1, 0, 0)
NR,Not reported;CPB, cardiopulmonary bypass;NA, not applicable; preop, preoperatively; contd, continued; postop, postoperatively. *Or angiotensin II receptor blockers. yValve
surgery with or without coronary artery bypass grafting. zJadad score presented as overall score with subscores for randomization (up to 2 points), double-blinding (up to 2 points),
description of withdrawals (up to 1 point), and (overall score).
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shorter hospital stay (0.66 days) after cardiac surgery. Sta-
tistically nonsignificant reductions in ICU stay were also ob-
served. Because of the small number of studies and patients
included in this later mentioned analysis, however, it may be
premature to conclude that statins do not reduce ICU stay as
well.
Inflammation has been postulated as among the mecha-
nisms underlying the development of postoperative AF in
patients undergoing cardiac surgery.1,7-9 Because current
evidence suggests that statins have potent anti-
inflammatory effects in cardiac surgical patients,25-27 the
significant 43% RR reduction in postoperative AF seen in
this current meta-analysis provides further evidence support-
ing the therapeutic benefits derived from using agents that at-
tenuate the inflammatory response. In particular,
corticosteroids,28-30 polyunsaturated n-3 fatty acids,31,32
nonsteroidal anti-inflammatory drugs,33 and N-acetylcys-
teine34 are all anti-inflammatory agents previously shown
to be efficacious in reducing postoperative AF, with RR re-
ductions ranging from 20%34 to 66%.33
A study by Plenge and colleagues35 evaluating the time to
onset of statins’ anti-inflammatory effects suggests that their
effects are not of acute onset but rather occur with time. In
this study, a profound anti-inflammatory effect with simvas-
tatin 40 mg (measured by high-sensitivity C-reactive protein
lowering) was not apparent until around day 7 and did not
reach statistical significance until day 14. Thus this trial sug-
gests that the earlier a statin can be initiated before surgery,
the more profound will be the antifibrillatory benefit
achieved by patients. To the best of our knowledge, ours
is the first analysis of any kind to assess whether a relation-
ship in fact exists between preoperative duration of statin use
and effect on postoperative AF. Of note, we demonstrated
a both statistically and clinically significant duration–effect
interaction, equating to approximately a 3% risk reduction
in postoperative AF per preoperative day of statin use
(P ¼ .008). Although this finding is provocative, it needs
to be confirmed in a randomized trial.368 The Journal of Thoracic and Cardiovascular SurgPrevious research has suggested that a dose–response re-
lationship with statins and postoperative AF may also
exist.36-38 Lertsburapa and colleagues36 conducted a nested
case–control study with data from the randomized, con-
trolled Atrial Fibrillation Suppression Trials I, II, and III
and found that higher statin doses (atorvastatin equivalent
dose 40 mg/d) were associated with greater reduction in
postoperative AF than were lower doses. This finding was
later corroborated by observational studies conducted by
Kourliouros and associates37 and Mathani and coworkers.38
Our metaregression analysis failed to confirm the findings of
these 3 studies (P ¼ .47). Despite this failure, however, we
cannot rule out the possibility that such a relationship does in
fact exist, because our analysis contained only a few studies
and may have been underpowered to detect it.
Some limitations to this meta-analysis should be noted.
First, it is possible that preoperative statin use in included tri-
als is serving as a surrogate for higher socioeconomic status.
Because better socioeconomic status has been found to be
associated with decreased postoperative complications in
patients undergoing cardiac surgery, it is possible that our
findings do not represent a innate benefit of statins.39,40
Second, publication bias is always a concern when
conducting a meta-analysis.15 Because of the small number
of trials included in our meta-analysis, it was difficult to rule
out the presence of publication bias solely by visual inspec-
tion of funnel plots. That being said, Egger’s regression sta-
tistic P values did suggest that publication bias was less
likely, and trim and fill analyses suggested that any publica-
tion bias present was not likely to affect overall study con-
clusions. Next, because of sparse and inconsistent
reporting across trials, we were unable to assess the impact
of heterogeneous definitions of postoperative AF or varia-
tions in the use of routine prophylactic therapies (eg, b-
blockers, amiodarone) on our meta-analytic conclusions.
With respect to the latter of these limitations, because b-
blockers and amiodarone do not reduce postoperative AF
through anti-inflammatory mechanisms, we would expect
any interaction with statins to be minimal. Finally, weery c August 2010
FIGURE 2. Statins’ effects on postoperative atrial fibrillation (A), intensive care unit stay (B), and total hospital stay (C). All pooled results were calculated
with DerSimonian and Laird random-effects model. RR, Relative risk; CI, confidence interval; WMD, weighted mean difference.
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TABLE 2. Results of sensitivity analyses
Stay, weighted mean difference
POAF Intensive care Total
Base case
Relative risk 0.57 0.17 0.66
95% CI 0.45–0.72 0.37–0.03 1.01 to0.30
Excluding studies allowing valve surgery
Relative risk 0.51 0.17 0.67
95% CI 0.35–0.74 0.37–0.03 1.19 to0.14
Excluding studies allowing off-pump surgery
Relative risk 0.58 0.19 0.69
95% CI 0.45–0.75 0.41–0.03 1.08 to0.29
With fixed-effect model
Relative risk 0.56 0.20 0.68
95% CI 0.44–0.71 0.36 to0.04 0.91 to0.46
Trim and fill analysis
Relative risk 0.57 0.25 0.66
95% CI 0.45–0.73 0.46 to0.03 1.01 to0.30
Excluding studies at extremes* control risk
Relative risk 0.51 0.16 0.67
95% CI 0.36–0.74 0.39–0.06 1.19 to0.14
Jadad score<3
Relative risk 0.56 0.27 0.71
95% CI 0.44–0.72 0.45 to0.09 1.08 to0.35
POAF, Postoperative atrial fibrillation; CI, confidence interval. *Control risks 5% for
Tamayo, 57% for Patti (mean control risk 31%).
TABLE 3. Risk ratio of postoperative atrial fibrillation associated
with statin use by increasing increments in preoperative statin
duration
Duration (d) Risk ratio*
2 0.59
3 0.57
7 0.51
14 0.42
21 0.34
*Derived from the following equation: Ln(RR) ¼0.0283 3 D0.4781, where RR
represents risk ratio and D represents duration in days (P ¼.008).
General Thoracic Surgery Chen et al
G
T
Swere not able to assess additional clinical end points, includ-
ing stroke, myocardial infarction, and death, because of spo-
radic reporting and low event rates. Larger clinical trials will
be required to evaluate these end points in the future.CONCLUSIONS
Evidence suggests that statins are associated with a re-
duced risk of postoperative AF and a shorter hospital stay af-Ln RR = -0.0283* (Duration) - 0.4781
p=0.008-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
5101505- 5202
Days
Ln RR
FIGURE 3. Risk ratio (RR) of postoperative atrial fibrillation associated
with duration of preoperative statin use. Greater weight of study corre-
sponds to larger area of circle and to greater contribution of study to overall
pooled effect. Superimposed line was obtained by conducting random-
effects metaregression analysis with restricted maximum likelihood method
to estimate residual variance resulting from heterogeneity.
370 The Journal of Thoracic and Cardiovascular Surgter cardiac surgery. Data also suggest that earlier therapy
results in more profound benefit. Unfortunately, this meta-
analysis of relatively small trials does not provide definitive
proof of any statin’s antifibrillatory benefit. Moreover, the
optimal duration and dose of perioperative statins are still
a matter of debate. Larger randomized, controlled trials de-
signed to compare different dosing intensities and lengths
of statin therapy should therefore be conducted in the future.
We thank Dr Caorsi and colleagues for providing additional data
pertaining to their trial.
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Appendix 1. MEDLINE in OVID Search Strategy
1. Hydroxymethylglutaryl-CoA Reductase Inhibitors/ or
hydroxymenthylglutaryl-CoA Reductase inhibitor.mp.
or hydroxymethylglutaryl-CoA Reductase inhibi-
tors.mp. or HMG CoA reductase inhibitors.mp. or
HMG CoA reductase inhibitor.mp.
2. (statins or statin).mp.
3. (atorvastatin or fluvastatin or lovastatin or pravastatin or
rosuvastatin or simvastatin or pitavastatin).mp. [mp¼ti,
ab, tx, kw, ct, ot, sh, hw, nm]
4. 1 or 2 or 3
5. thoracic surgery.mp. or Thoracic Surgery/
6. (cardiac surgery or heart surgery or cardiac thoracic sur-
gery or open heart surgery).mp. [mp¼ti, ab, tx, kw, ct,
ot, sh, hw, nm]
7. cardiopulmonary bypass.mp. or Cardiopulmonary
Bypass/
8. (cardiopulmonary bypasses or heart-lung bypass or
heart-lung bypasses).mp.
9. coronary artery bypass.mp. or Coronary Artery Bypass/
10. (coronary artery bypasses or coronary artery bypass
grafting or CABG or aortocoronary bypass or aorto-
coronary bypasses or coronary artery bypass surger-
y).mp.
11. (valve replacement or valve surgery or valvular
surgery).mp.
12. 5 or 6 or 7 or 8 or 9 or 10 or 11
13. 4 and 12
14. (randomized controlled trial or controlled clinical tri-
al).pt. or randomized.ab. or placebo.ab. or drug thera-
py.fs. or randomly.ab. or trial.ab. or group.ab.
15. (animals not (humans and animals)).sh.
16. 14 not 15
17. 16 and 13
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